581772-29-4

Basic information

• Product Name: Atorvastatin Acetonide
• Synonyms: Atorvastatin Acetonide;(4R,6R)-6-[2-[2-(4-Fluorophenyl)-5-(1-Methylethyl)-3-phenyl-4-[(phenylaMino)carbonyl]-1H-pyrrol-1-yl]ethyl]-2,2-diMethyl-1,3-dioxane-4-acetic Acid;Atorvastatin Acetonide Acid;Atorvastatin IMpurity 2;Atorvastatin 3;2-((4R,6R)-6-(2-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)et;Atorvastatin Impurity 30
• CAS NO: 581772-29-4
• Molecular Formula: C₃₆H₃₉FN₂O₅
• Molecular Weight: 598.7036632
• Product Categories: Chiral Reagents;Intermediates;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 581772-29-4.mol
• Article Data: 13

Chemical Properties

• Melting Point: 73-75°C
• Boiling Point: 689.3±55.0 °C(Predicted)
• Appearance: /
• Density: 1.21±0.1 g/cm3(Predicted)
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)
• PKA: 4.24±0.10(Predicted)
• CAS DataBase Reference: Atorvastatin Acetonide(CAS DataBase Reference)
• NIST Chemistry Reference: Atorvastatin Acetonide(581772-29-4)
• EPA Substance Registry System: Atorvastatin Acetonide(581772-29-4)

Safety Data

• Hazardous Substances Data: 581772-29-4(Hazardous Substances Data)

Usage

Chemical Properties

Off-White to Pale Yellow Solid

Uses

Protected Atorvastatin.

Upstream product

• 7342-02-1 3-phenylpropynoic acid phenylamide 
• 459-57-4 4-fluorobenzaldehyde 
• 125971-86-0 tert-butyl [(4R,6R)-6-aminoethyl-2,2-dimethyl-1,3-dioxan-4-yl]acetate 
• 204448-48-6 tert-butyl (R)-1-(benzyloxy)hex-5-en-3-yl carbonate 
• 111322-01-1 (R)-1-benzyloxy-hex-5-en-3-ol 
• 697266-08-3 5-(4-fluorophenyl)-1-{2-[(4R,6S)-6-(2-hydroxyethyl)-2,2-dimethyl-1,3-dioxan-4-yl]ethyl}-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide 
• 1262052-14-1 1-(2-{(4R,6S)-6-[2-(benzyloxy)ethyl]-2,2-dimethyl-1,3-dioxan-4-yl}ethyl)-5-(4-fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide 
• 1262052-10-7 2-{(4R,6S)-6-[2-(benzyloxy)ethyl]-2,2-dimethyl-1,3-dioxan-4-yl}ethylamine 
• 114861-21-1 2,3-dideoxy-3,5-O-(1-methylethylidene)-1-O-(phenylmethyl)-D-erythro-hexitol 
• 77-76-9 2,2-dimethoxy-propane 
• 345891-62-5 (3R,5R)-methyl 7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate 
• 134523-03-8 lipitor 
• 134523-00-5 atorvastatin 
• 1353049-81-6 methyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 

Downstream Products

• 1345092-29-6 (Z)-4-hydroxybut-2-enyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 
• 1345091-91-9 (3R,5R)-((Z)-4-((1-(nitrooxy)ethoxy)carbonyloxy)but-2-enyl) 7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate 
• 1345092-31-0 (3R,5R)-((Z)-4-((1-chloroethoxy)carbonyloxy)but-2-enyl) 7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate 
• 1345092-30-9 (3R,5R)-((Z)-4-hydroxybut-2-enyl) 7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate 
• 1353049-82-7 3,3-dimethyl-5,6-bis (nitrooxy)hexyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 
• 1353048-94-8 (3R,5R)-3,3-dimethyl-5,6-bis(nitrooxy)hexyl 7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate 
• 501121-34-2 (-)-Atorvastatin 

Relevant articles and documents

GlcNAc Conjugated Atorvastatin with Enhanced Water Solubility and Cellular Internalization

Targeting ligands facilitate cell specific drug delivery and improve pharmaceutical properties. Herein, we designed two ligand drug conjugates by conjugating GlcNAc (N-acetylglucosamine) with atorvastatin. These two conjugates, termed G-AT and G-K-AT, exhibited enhanced water solubility and cellular uptake. Moreover, both G-AT and G-K-AT were able to release atorvastatin and consequently achieve significant inhibition against 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase.

Rapid Asymmetric Synthesis of Disubstituted Allenes by Coupling of Flow-Generated Diazo Compounds and Propargylated Amines

We report herein the asymmetric coupling of flow-generated unstabilized diazo compounds and propargylated amine derivatives, using a new pyridinebis(imidazoline) ligand, a copper catalyst and base. The reaction proceeds rapidly, generating chiral allenes in 10–20 minutes with high enantioselectivity (89–98 % de/ee), moderate yields and a wide functional group tolerance.

METHODS FOR PROVIDING INTERMEDIATES IN THE SYNTHESIS OF ATORVASTATIN.

The invention relates to the field of medicinal chemistry, In particular, it relates to methods for providing intermediates in the synthesis of Atorvastatin, a competitive inhibitor of HMG-Co A reductase. Provided is a process for providing a compound having a Formula (I) or a pharmaceutically acceptable salt, ester, amide or stereoisomer thereof, comprising reacting in a 4 component Ugi-reaction in a single reaction mixture the compounds of formula A, formula B, formula C and formula D.